

# Jonathan Douxfils

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6053807/publications.pdf>

Version: 2024-02-01

171  
papers

5,517  
citations

81434

41  
h-index

116156

66  
g-index

186  
all docs

186  
docs citations

186  
times ranked

6226  
citing authors

#	ARTICLE	IF	CITATIONS
1	Importance of sample dilution in the evaluation of the antibody response after SARS-CoV-2 vaccination. <i>Journal of Infection</i> , 2022, 84, 94-118.	1.7	3
2	Study of in vitro thrombin generation after neutralization of heparin. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 168-176.	0.7	8
3	Simultaneous assessment of DOACs effect on clot formation and fibrinolysis with the FibWave. <i>International Journal of Laboratory Hematology</i> , 2022, 44, .	0.7	1
4	Effect of tissue factor pathway inhibitor on thrombin generation assay. <i>International Journal of Laboratory Hematology</i> , 2022, 44, .	0.7	0
5	Nucleocapsid serum antigen determination in SARS-CoV-2 infected patients using the single molecule array technology and prediction of disease severity. <i>Journal of Infection</i> , 2022, 84, e4-e6.	1.7	4
6	Spike vs. nucleocapsid serum antigens for COVID-19 diagnosis and severity assessment. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, e97-e100.	1.4	5
7	Stability of coagulation parameters in plasma samples at room temperature after one freeze/thaw cycle. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 610-618.	0.7	4
8	Identification of SARS-CoV-2 Neutralizing Antibody with Pseudotyped Virus-based Test on HEK-293T hACE2 Cells. <i>Bio-protocol</i> , 2022, 12, e4377.	0.2	7
9	Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 121-137.	1.3	33
10	Uninterrupted DOACs Approach for Catheter Ablation of Atrial Fibrillation: Do DOACs Levels Matter?. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 864899.	1.1	1
11	Analytical performance of the endogenous thrombin potentialâ€‘based activated protein C resistance assay on the automated ST Genesis system. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12684.	1.0	4
12	The edoxabanâ€‘M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12680.	1.0	1
13	Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, e153-e156.	1.4	7
14	Analytical Sensitivity of Six SARS-CoV-2 Rapid Antigen Tests for Omicron versus Delta Variant. <i>Viruses</i> , 2022, 14, 654.	1.5	44
15	Performance of a Qualitative Point-of-Care Strip Test to Detect DOAC Exposure at the Emergency Department: A Cohort-Type Cross-Sectional Diagnostic Accuracy Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1723-1731.	1.8	6
16	Liquid Biopsy in Glioblastoma. <i>Cancers</i> , 2022, 14, 3394.	1.7	17
17	Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19â€‘BNT162b2 mRNA Vaccination. <i>Viruses</i> , 2022, 14, 1470.	1.5	5
18	Assessment of acquired activated protein C resistance with the FibWave and comparison with the ETPâ€‘based APC resistance. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 802-812.	0.7	3

#	ARTICLE	IF	CITATIONS
19	Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies. <i>Journal of Medical Virology</i> , 2021, 93, 803-811.	2.5	77
20	Are the DOAC plasma level thresholds appropriate for clinical decision-making? A reappraisal using thrombin generation testing. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e48-e51.	0.7	11
21	Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 297-303.	1.9	27
22	Clinical performance of three fully automated anti-SARS-CoV-2 immunoassays targeting the nucleocapsid or spike proteins. <i>Journal of Medical Virology</i> , 2021, 93, 2262-2269.	2.5	20
23	Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study. <i>Thrombosis Research</i> , 2021, 197, 20-23.	0.8	36
24	Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 7-20.	0.7	23
25	Head-to-Head Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2 Infection. <i>Journal of Clinical Medicine</i> , 2021, 10, 265.	1.0	77
26	Antibody titres decline 3-month post-vaccination with BNT162b2. <i>Emerging Microbes and Infections</i> , 2021, 10, 1495-1498.	3.0	141
27	Influence of C-reactive protein on thrombin generation assay. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e301-e305.	1.4	1
28	2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1008-1020.	1.8	94
29	Clinical performance of the Panbio assay for the detection of SARS-CoV-2 IgM and IgG in COVID-19 patients. <i>Journal of Medical Virology</i> , 2021, 93, 3277-3281.	2.5	7
30	Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. <i>Microorganisms</i> , 2021, 9, 556.	1.6	52
31	Viscoelastometric Testing to Assess Hemostasis of COVID-19: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 1740.	1.0	43
32	Comparison is not reason: Pitfalls in reporting thrombin generation results in anticoagulated patients. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12523.	1.0	0
33	Evaluations of SARS-CoV-2 Serological Assay Performance Need Inclusion of Long-Term Samples. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	1.8	6
34	Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2. <i>Microorganisms</i> , 2021, 9, 1340.	1.6	33
35	Impact of centrifugation on thrombin generation in healthy subjects and in patients treated with direct oral anticoagulants. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1585-1592.	0.7	2
36	Detection of Direct Oral Anticoagulants in Patient Urine Samples by Prototype and Commercial Test Strips for DOACs – A Systematic Review and Meta-analysis. <i>TH Open</i> , 2021, 05, e438-e448.	0.7	7

#	ARTICLE	IF	CITATIONS
37	Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. <i>Thrombosis Research</i> , 2021, 203, 163-171.	0.8	52
38	Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2. <i>Viruses</i> , 2021, 13, 1364.	1.5	72
39	Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rationale for monitoring immunoglobulin G levels. <i>Haematologica</i> , 2021, 106, 3249-3252.	1.7	9
40	Reply to Schulte-Pelkum, J. Comment on "Favresse et al. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. <i>Microorganisms</i> 2021, 9, 556" <i>Microorganisms</i> , 2021, 9, 1849.	1.6	3
41	Efficient Maternal to Neonate Transfer of Neutralizing Antibodies after SARS-CoV-2 Vaccination with BNT162b2: A Case-Report and Discussion of the Literature. <i>Vaccines</i> , 2021, 9, 907.	2.1	9
42	NETosis and the Immune System in COVID-19: Mechanisms and Potential Treatments. <i>Frontiers in Pharmacology</i> , 2021, 12, 708302.	1.6	37
43	Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2). <i>Clinical Microbiology and Infection</i> , 2021, 27, 1351.e5-1351.e7.	2.8	54
44	Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers. <i>Vaccines</i> , 2021, 9, 1092.	2.1	96
45	The Impact of Strong Inducers on Direct Oral Anticoagulant Levels. <i>American Journal of Medicine</i> , 2021, 134, 1295-1299.	0.6	16
46	Post-SARS-CoV-2 vaccination specific antibody decrease " Thresholds for determining seroprevalence and seroneutralization differ. <i>Journal of Infection</i> , 2021, 83, e4-e5.	1.7	20
47	An original multiplex method to assess five different SARS-CoV-2 antibodies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 971-978.	1.4	15
48	Long-term kinetics of anti-SARS-CoV-2 antibodies in a cohort of 197 hospitalized and non-hospitalized COVID-19 patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e179-e183.	1.4	15
49	Estetrol (E4) is a native fetal estrogen that does not modify coagulation markers in postmenopausal women and maintains sensitivity to activated protein C (APC). <i>Maturitas</i> , 2021, 152, 69.	1.0	3
50	Cytokine storm induced coagulopathy in septic shock and critical Covid-19: head-to-head comparison. <i>European Heart Journal</i> , 2021, 42, .	1.0	0
51	Usefulness of a Non-Streptavidin Bead Technology to Overcome Biotin Interference: Proof of Principle with 25-OH Vitamin D, TSH, and FT4. <i>Journal of Applied Laboratory Medicine</i> , The, 2021, 6, 1072-1077.	0.6	1
52	Interlaboratory variability of activated protein C resistance using the ETP-based APC resistance assay. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12612.	1.0	6
53	Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects. <i>Viruses</i> , 2021, 13, 2329.	1.5	13
54	Inflammation-Induced Coagulopathy Substantially Differs Between COVID-19 and Septic Shock: A Prospective Observational Study. <i>Frontiers in Medicine</i> , 2021, 8, 780750.	1.2	9

#	ARTICLE	IF	CITATIONS
55	Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk. <i>Frontiers in Endocrinology</i> , 2021, 12, 769187.	1.5	49
56	Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rationale for monitoring immunoglobulin G levels. <i>Haematologica</i> , 2021, , .	1.7	1
57	Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urineâ€”A Multicenter Trial. <i>Thrombosis and Haemostasis</i> , 2020, 120, 132-140.	1.8	30
58	Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 294-305.	1.4	30
59	High clinical performance and quantitative assessment of antibody kinetics using a dual recognition assay for the detection of SARS-CoV-2 IgM and IgG antibodies. <i>Clinical Biochemistry</i> , 2020, 86, 23-27.	0.8	22
60	An Original ELISA-Based Multiplex Method for the Simultaneous Detection of 5 SARS-CoV-2 IgG Antibodies Directed against Different Antigens. <i>Journal of Clinical Medicine</i> , 2020, 9, 3752.	1.0	30
61	Prothrombotic hemostasis disturbances in patients with severe COVID-19: Individual daily data. <i>Data in Brief</i> , 2020, 33, 106519.	0.5	19
62	Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. <i>Cancer Medicine</i> , 2020, 9, 6565-6575.	1.3	29
63	Can We Measure the Individual Prothrombotic or Prohemorrhagic Tendency by Global Coagulation Tests?. <i>Hamostaseologie</i> , 2020, 40, 364-378.	0.9	8
64	Letter to the Editors-in-Chief in response to the article of Abou-Ismaïl, et al. entitled "Estrogen and thrombosis: A bench to bedside review" (Thrombosis Research 192 (2020) 40â€”51). <i>Thrombosis Research</i> , 2020, 193, 221-223.	0.8	12
65	Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory. <i>Thrombosis Journal</i> , 2020, 18, 17.	0.9	52
66	Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. <i>Contraception</i> , 2020, 102, 396-402.	0.8	52
67	Overview and Practical Application of Coagulation Assays in Managing Anticoagulation with Direct Oral Anticoagulants (DOACs). <i>Current Pharmacology Reports</i> , 2020, 6, 241-259.	1.5	10
68	Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance, and their limitations. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3121-3124.	1.9	16
69	Potential Drug Interactions between Recombinant Interleukin-2 and Direct Oral Anticoagulants: Indirect Evidence from In Vivo Animal Studies. <i>Hamostaseologie</i> , 2020, 40, 679-686.	0.9	1
70	The role of serology for COVID-19 control: Population, kinetics and test performance do matter. <i>Journal of Infection</i> , 2020, 81, e91-e92.	1.7	26
71	Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis. <i>Cancers</i> , 2020, 12, 1242.	1.7	9
72	Clinical Performance of the Elecsys Electrochemiluminescent Immunoassay for the Detection of SARS-CoV-2 Total Antibodies. <i>Clinical Chemistry</i> , 2020, 66, 1104-1106.	1.5	103

#	ARTICLE	IF	CITATIONS
73	Evaluation of the analytical performances of FibWave, a new sensitive tool assessing the fibrin clot formation, to measure the effects of anticoagulants. <i>Thrombosis Research</i> , 2020, 191, 78-81.	0.8	5
74	Unexpected kinetics of anti-SARS-CoV-2 total antibodies in two patients with chronic lymphocytic leukemia. <i>British Journal of Haematology</i> , 2020, 190, e187-e189.	1.2	11
75	The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 1007.	1.6	16
76	Neutralization of biotin interference: preliminary evaluation of the VeraTest Biotin <sup>®</sup> , VeraPrep Biotin <sup>®</sup> , and BioT-Filter <sup>®</sup> . <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, e130-e133.	1.4	9
77	Proof of concept of a new scale for the harmonization and the standardization of the ETP-based APC resistance. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 895-904.	1.9	10
78	Importance of measuring pharmacologically active metabolites of edoxaban: development and validation of an ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 395-403.	1.0	7
79	Assessment of low plasma concentrations of apixaban in the periprocedural setting. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 394-402.	0.7	5
80	Ecarin based coagulation testing. <i>American Journal of Hematology</i> , 2020, 95, 863-869.	2.0	19
81	Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 872-886.	1.5	18
82	Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1357-1364.	1.4	80
83	Response of anti-SARS-CoV-2 total antibodies to nucleocapsid antigen in COVID-19 patients: a longitudinal study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, e193-e196.	1.4	18
84	Concomitant assessment of rivaroxaban concentration and its impact on thrombin generation. <i>Thrombosis Research</i> , 2019, 184, 8-15.	0.8	4
85	Anticoagulation With an Inhibitor of Factors XIa and XIIa During Cardiopulmonary Bypass. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2178-2189.	1.2	31
86	Assessment of the analytical performances and sample stability on ST Genesis system using the STG <sup>®</sup> DrugScreen application. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1273-1287.	1.9	43
87	An update on laboratory assessment for direct oral anticoagulants (DOACs). <i>International Journal of Laboratory Hematology</i> , 2019, 41, 33-39.	0.7	59
88	Clotting test results correlate better with DOAC concentrations when expressed as a <sup>®</sup> Correction Ratio <sup>®</sup> results before/after extraction with the DOAC Stop reagent. <i>Thrombosis Research</i> , 2019, 179, 69-72.	0.8	9
89	Andexanet alfa for the reversal of factor Xa inhibitors. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 387-397.	1.4	10
90	Optimal wavelength for the clot waveform analysis: Determination of the best resolution with minimal interference of the reagents. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 316-324.	0.7	9

#	ARTICLE	IF	CITATIONS
91	Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAME-TT2-R2 Score: An Analysis of Hokusai-VTE. <i>Thrombosis and Haemostasis</i> , 2019, 119, 675-684.	1.8	9
92	PS1188 AN UPDATED META-ANALYSIS OF THE RISKS OF ARTERIAL AND VENOUS OCCLUSIVE EVENTS WITH NEW GENERATION BCR-ABL TKIS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA. <i>HemaSphere</i> , 2019, 3, 541.	1.2	0
93	Prospective and comparative study of paroxysmal nocturnal hemoglobinuria patients treated or not by eculizumab. <i>Medicine (United States)</i> , 2019, 98, e16164.	0.4	2
94	Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 250-261.	0.7	9
95	Determinants of the Quality of Warfarin Control and Validation of the SAME-TT2-R2 Score for Acute Venous Thromboembolism. An Analysis of the Hokusai-VTE Trial. , 2019, 39, .		0
96	BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?. <i>TH Open</i> , 2018, 02, e68-e88.	0.7	21
97	International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. <i>Thrombosis and Haemostasis</i> , 2018, 118, 437-450.	1.8	268
98	The DaXa-inhibition assay: A concept for a readily available, universal aXa assay that measures the direct inhibitory effect of all anti-Xa drugs. <i>Thrombosis Research</i> , 2018, 168, 63-66.	0.8	14
99	Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 129-138.	0.7	22
100	Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 209-219.	1.9	266
101	Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. <i>Thrombosis Journal</i> , 2018, 16, 28.	0.9	63
102	The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generation. <i>Thrombosis Research</i> , 2018, 171, 160-166.	0.8	21
103	Evaluation of the DOAC-Stop® Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests. <i>TH Open</i> , 2018, 02, e202-e209.	0.7	54
104	Betrixaban: Impact on Routine and Specific Coagulation Assays – A Practical Laboratory Guide. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1203-1214.	1.8	21
105	Reduction of the turn-around time for the measurement of rivaroxaban and apixaban: Assessment of the performance of a rapid centrifugation method. <i>International Journal of Laboratory Hematology</i> , 2018, 40, e105-e108.	0.7	10
106	Application of a clot-based assay to measure the procoagulant activity of stored allogeneic red blood cell concentrates. <i>Blood Transfusion</i> , 2018, 16, 163-172.	0.3	4
107	Laboratory Assessment of Direct Oral Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 277-290.	1.5	75
108	Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels. <i>Thrombosis Research</i> , 2017, 156, 36-38.	0.8	25

#	ARTICLE	IF	CITATIONS
109	Perioperative management of patients on direct oral anticoagulants. <i>Thrombosis Journal</i> , 2017, 15, 14.	0.9	92
110	Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 237-245.	0.6	11
111	Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme. <i>International Journal of Laboratory Hematology</i> , 2017, 39, 402-408.	0.7	24
112	Inactivation of human coagulation factor X by a protease of the pathogen <i>Capnocytophaga canimorsus</i> . <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 487-499.	1.9	10
113	Measuring Direct Oral Anticoagulants. <i>Methods in Molecular Biology</i> , 2017, 1646, 217-225.	0.4	7
114	Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1275-1296.	1.4	10
115	An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants. <i>Thrombosis Research</i> , 2017, 157, 29-37.	0.8	14
116	Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 5-12.	1.0	48
117	Impact of the Direct Oral Anticoagulants on Activated Clotting Time. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2017, 31, e24-e27.	0.6	15
118	Clinical pearls: Laboratory assessments of direct oral anticoagulants (DOACS). <i>Hamostaseologie</i> , 2017, 37, 295-301.	0.9	10
119	Edoxaban: Impact on routine and specific coagulation assays. <i>Thrombosis and Haemostasis</i> , 2016, 115, 368-381.	1.8	61
120	Heparin monitoring: clinical outcome and practical approach. <i>Annales De Biologie Clinique</i> , 2016, 74, 637-652.	0.2	4
121	Periprocedural Management of Direct Oral Anticoagulants Should Be Guided by Accurate Laboratory Tests. <i>Regional Anesthesia and Pain Medicine</i> , 2016, 41, 787-788.	1.1	5
122	Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia—Reply. <i>JAMA Oncology</i> , 2016, 2, 829.	3.4	4
123	Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival. <i>JAMA Oncology</i> , 2016, 2, 625.	3.4	158
124	Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or useless?. <i>TrAC - Trends in Analytical Chemistry</i> , 2016, 84, 41-50.	5.8	17
125	Real-world variability in dabigatran levels in patients with atrial fibrillation: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1166-1168.	1.9	3
126	Influence of dabigatran and rivaroxaban on routine coagulation assays. <i>Thrombosis and Haemostasis</i> , 2015, 113, 154-164.	1.8	73



#	ARTICLE	IF	CITATIONS
127	Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations. <i>BioMed Research International</i> , 2015, 2015, 1-13.	0.9	35
128	Target-Specific Oral Anticoagulants – New Approaches in the Field of Oral Anticoagulation. <i>BioMed Research International</i> , 2015, 2015, 1-1.	0.9	1
129	Estimation of dabigatran plasma concentrations in the perioperative setting. <i>Thrombosis and Haemostasis</i> , 2015, 113, 862-869.	1.8	53
130	Dose tailoring of dabigatran etexilate: obvious or excessive?. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1283-1289.	1.0	22
131	Criteria for Prescribing Dabigatran Etexilate and Rivaroxaban Really Appropriate? Authors' Reply. <i>Annals of Pharmacotherapy</i> , 2015, 49, 155-155.	0.9	1
132	Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study. <i>Thrombosis Research</i> , 2015, 136, 693-696.	0.8	28
133	Large external quality assessment survey on thrombin generation with CAT: further evidence for the usefulness of normalisation with an external reference plasma. <i>Thrombosis Research</i> , 2015, 136, 125-130.	0.8	57
134	Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study. <i>Thrombosis Research</i> , 2015, 135, 852-860.	0.8	26
135	Effects of dietary linseed oil on innate immune system of Eurasian perch and disease resistance after exposure to <i>Aeromonas salmonicida</i> achromogen. <i>Fish and Shellfish Immunology</i> , 2015, 47, 782-796.	1.6	16
136	Corticosteroids and the Stress Response in Percid Fish. , 2015, , 725-742.		3
137	Domestication and Responses to Stress. , 2015, , 743-760.		6
138	BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis on the Risk of Cardiovascular Events, Major Molecular Response and Overall Survival. <i>Blood</i> , 2015, 126, 2785-2785.	0.6	4
139	Erratum to "Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants". <i>BioMed Research International</i> , 2014, 2014, 1-1.	0.9	8
140	Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting. <i>BioMed Research International</i> , 2014, 2014, 1-16.	0.9	23
141	Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	6
142	Appropriateness of Prescribing Dabigatran Etexilate and Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1258-1268.	0.9	81
143	Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. <i>Thrombosis Journal</i> , 2014, 12, 24.	0.9	45
144	Comparison of five D-dimer reagents and application of an age-adjusted cut-off for the diagnosis of venous thromboembolism in emergency department. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 309-315.	0.5	30

#	ARTICLE	IF	CITATIONS
145	Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All-Cause Mortality: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2014, 3, e000515.	1.6	85
146	Platelet microparticle generation assay: A valuable test for immune heparin-induced thrombocytopenia diagnosis. <i>Thrombosis Research</i> , 2014, 133, 1068-1073.	0.8	36
147	Influence of domestication process on immune response to repeated emersion stressors in Eurasian perch ( <i>Perca fluviatilis</i> , L.). <i>Comparative Biochemistry and Physiology Part A, Molecular &amp; Integrative Physiology</i> , 2014, 173, 52-60.	0.8	16
148	Rapid exclusion of the diagnosis of immune HIT by AcuStar HIT and heparin-induced multiple electrode aggregometry. <i>Thrombosis Research</i> , 2014, 133, 1074-1078.	0.8	23
149	Estimation of Dabigatran Plasma Concentrations in the Perioperative Setting. an Ex-Vivo Study Using Dedicated Coagulation Assays. <i>Blood</i> , 2014, 124, 1549-1549.	0.6	1
150	Assessment of the performances of AcuStar HIT and the combination with heparin-induced multiple electrode aggregometry: A retrospective study. <i>Thrombosis Research</i> , 2013, 132, 352-359.	0.8	25
151	Immune response of gravid Eurasian perch to isolation and confinement rearing conditions. <i>Fish and Shellfish Immunology</i> , 2013, 34, 1723.	1.6	0
152	Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 7107-7117.	1.4	56
153	Repeated water emersions and domestication have no marked influence on stress physiology but modulate the abundance of several immune proteins in Eurasian perch. <i>Fish and Shellfish Immunology</i> , 2013, 34, 1649-1650.	1.6	0
154	Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. <i>Thrombosis and Haemostasis</i> , 2013, 110, 283-294.	1.8	179
155	Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , 2013, 110, 543-549.	1.8	92
156	Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2013, 110, 723-731.	1.8	141
157	Is Dilute Russell's Viper Venom Time a Useful Assay To Monitor Patients Treated By Rivaroxaban Or Dabigatran Etexilate?. <i>Blood</i> , 2013, 122, 3634-3634.	0.6	0
158	Dabigatran Etexilate and Risk Of Myocardial Infarction, Major Bleeding and All-Cause Mortality: A Systematic Review and Meta-Analysis Of Randomized Controlled Trials. <i>Blood</i> , 2013, 122, 3633-3633.	0.6	0
159	Is Thrombin Time Useful To Guide Peri-Procedural Management For Patients On Dabigatran Etexilate?: An In Vitro Validation Study. <i>Blood</i> , 2013, 122, 2388-2388.	0.6	0
160	Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature. <i>Thrombosis Research</i> , 2012, 130, 956-966.	0.8	201
161	Impact of dabigatran on a large panel of routine or specific coagulation assays. <i>Thrombosis and Haemostasis</i> , 2012, 107, 985-997.	1.8	321
162	Fish welfare and genomics. <i>Fish Physiology and Biochemistry</i> , 2012, 38, 43-60.	0.9	44

